biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Sir_Holleron Aug 06, 2015 10:35am

129 Views

Post# 23994005

RE:RE:RE:New Video about Scarpa

It looks like a 6 week study and there didn't look to be much disease in the corpus collosum in either treatment or control group. Discarding that region and looking at the other brain regions in the graphs about half the disease still remained with Tanscendpep. We would need a longer study to further examine results over time. What does this mean for brain tumors in these regions, etc.? Can Transcend distribute effect equally across all regions of the brain given the brains complexity and a human brain is much, much more complex. Ideally I was hoping for a more overwhelming result in such a simple model as the mouse and I think BTI was too. It's a start and it will be interesting to see what further dosing experiments can do although this can take time given how long this study took. It would be nice to see an intrathecal control group too if that is the emerging competition.

~Comparing the human and mouse brain reveals why mapping the mouse brain is easier.